PREDICTIVE POTENTIAL OF IL28B GENE IN HCV PATIENTS, RESISTANT TO DACLATASVIR AND SOFOSBUVIR IN KPK POPULATION
DOI:
https://doi.org/10.55519/JAMC-04-11760Keywords:
IL28B, Hepatitis C, Genotype 3aAbstract
Background: Recently various combinations of direct acting antivirals (DAAs) have been tried successfully. Sofosbuvir + Daclatasvir combination has been used with promising results. Recently, resistance has been noticed against DAAs. Therefore, polymorphism at particular sites in the interleukin 28B gene are under study to find possible association with resistance. This study was aimed at finding out any association of SNPs rs8099917 and rs12979860 (IL28B gene) with response and resistance to treatment in HCV genotype 3 patients in Khyber Pakhtunkhwa. Methods: This cross sectional, Analytical study was conducted at Gastroenterology/hepatology OPD of Prime Teaching Hospital, Peshawar Medical College. Collected Samples were stored at -20o C in PCR Lab of the College. DNA extraction and genotyping was carried out at BJ Molecular Biology Lab in Rawalpindi. Data was analyzed by using SPSS version 21. Chi-Square Test was used to see the statistically significant differences between rs8099917 T/G and rs12979860 T/C model. Results: In the IL28-B gene, single nucleotide polymorphism at rs12979860 T/C model, we observed that there are 37.5% CC homozygous, 12.5% TT homozygous and 50% CT heterozygous genotypes in resistant patients and 42.85% CC homozygous, 28.57% TT and 28.57% CT genotype in responder group. In rs12979860 T/C model, genotype of IL28-B in the responder and resistant group significantly varies at p-value =0.00572. Conclusion: We conclude that in SNP at rs12979860, CC genotype is associated with clearance of HCV, while CT genotype was more prevalent in the resistant group and associated with chronicity.References
WHO fact sheet 2021. Hepatitis C. [Internet]. [cited 2023 Jan]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
American Association for the Study of Liver Diseases) and American Society of Infectious diseases society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.2017.
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370(20):1879–88.
Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infections. N Engl J Med 2015;373(27):2607.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211–21.
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373(8):714–25.
Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J Hepatol 2021;74(6):1472–82.
Ramadan A, Karam H, Abdel-Monem SS, Ahmed AM, Omar RM, Ahmed HR, et al. Evaluation of the safety and resistance associated variants of sofosbuvir/daclatasvir among egyptian patients with hepatitis C virus: a prospective study. Bull Pharm Sci 2022;45(2):1143–53.
Di Stefano M, Faleo G, Farhan Mohamed AM, Morella S, Bruno SR, Tundo P, et al. Resistance Associated Mutations in HCV Patients Failing DAA Treatment. New Microbiol 2021;44(1):12–8.
Raza H, Ahmad T, Afzal MS. HCV, Interferon Therapy Response, Direct Acting Antiviral Therapy Revolution and Pakistan: Future Perspectives. Asian Pac J Cancer Prev 2015;16(13):5583–4.
Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59(6):2403–12.
Imran M, Manzoor S, Ashraf J, Khalid M, Tariq M, Khaliq HM, et al. Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J 2013; 10:299.
Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, et al. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. Springerplus 2015; 4:357.
Murray MF. Chapter 39-susceptibility and response to infection. Emery and rimoin's principles and practice of medical genetics. 2013. [Internet]. [cited 2023 Jan]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/interleukin-28b
Afzal MS, Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World J Hepatol 2016;8(26):1116–8.
Justiz Vaillant AA, Qurie A. Interleukin. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2022 Jan-. [cited 2023 Jan]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499840/
Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani Hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis 2015; 30:91–7.
Hashmi AH, Ahmad N, Riaz S, Ali L, Siddiqi S, Khan KM, et al. Genotype CC rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection. Genes Immun 2014;15(6):430–2.
Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M. The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCVinfected Pakistani patients. J Dig Dis 2015;16(5):293–8.
Shaikh N, Waryah AM, Devrajani BR, Rajput MI, Hayat AS, Shaikh S. IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. J Med Virol 2015;87(5):814–20.
Imran M, Manzoor S, Azam S, Resham S. Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. APMIS 2015;123(4):342–49.
Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology - Clinical textbook. 10th Edition. [Internet]. Hamburg: Medizin Fokus Verlag, chapter 12, 2017: p.133–69. [cited 2023 Jan]. Available from: hepatology textbook.com/download/hepatology2020.pdf
Echeverría1 N, Chiodi D, López P, Ciceron AS, Angulo J, López-Lastra M, et al. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virol J 2018; 15:40.
Moghimi M, Tavakoli F, Doosti M, Ahmadi‑Vasmehjani A, Akhondi‑Meybodi M. Correlation between interleukin‑28 gene polymorphism with interleukin‑28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res Notes 2019; 12:626.
Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, et al. Simultaneous Genotyping of rs12979860 and rs8099917 Variants Near the IL28B Locus Associated with HCV Clearance and Treatment Response. J Mol Diagn 2011;13(4):446–51.
Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, et al. Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Responsein Chronic Hepatitis C. PLoS One 2014;9(11): e112592.
Additional Files
Published
Issue
Section
License
Copyright (c) 2023 Dr. Sunya Sardar, Professor Dr. Sardar Muhammad, Dr. Mohsina Haq, Professor Dr. Najib ul Haq, Dr. Arbab Muhammad Kashif khan
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
